Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)

被引：0
|
作者：
Martin, P. [1 ]
Armas, A. [2 ]
Gopal, A. [3 ]
Gyan, E. [4 ]
Wagner-Johnston, N. [5 ]
Walewski, J. [6 ]
Abella, S. [7 ]
Ye, W. [7 ]
Philip, B. [7 ]
Sorenson, B. [7 ]
de Vos, S. [8 ]
机构：
[1] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA
[2] Calaway Young Canc Ctr, Glenwood Springs, CO USA
[3] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
[4] Ctr Hosp Univ, Serv Hematol & Therapie Cellulaire, Tours, France
[5] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[6] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Lymphoproliferat Dis, Warsaw, Poland
[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
241
引用
下载
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [31] Clinic and treatment of different variants of lymphoma of the marginal zone (MZL)
    Lepkov, S.
    Subortceva, I.
    Zeynalova, P.
    Tumyn, G.
    Semenova, A.
    Kokosadze, N.
    Kuprishina, N.
    Kolomiytsev, O.
    Borisovsckay, S.
    Rybuhina, J.
    Kovrigina, A.
    Ettinger, O.
    Zaharov, O.
    Lazarev, I.
    Nikitin, I.
    Ivashenco, R.
    Urvantceva, O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 178 - 179
  • [32] The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial
    Chavez, Julio C.
    Goldschmidt, Neta
    Samaniego, Felipe
    Wrobel, Tomasz
    Cavallo, Federica
    Fonseca, Gustavo
    Yoon, Sung-Soo
    Drgona, Lubos
    Hawkes, Eliza
    Levi, Itai
    Miskin, Hari P.
    Sportelli, Peter
    O'Connor, Owen A.
    Fowler, Nathan H.
    Zinzani, Pier Luigi
    BLOOD, 2021, 138
  • [33] Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)
    Thieblemont, Catherine
    Wang, Kaijun
    Keeping, Sam
    Zhang, Ina
    Yang, Keri
    Tang, Boxiong
    Mohseninejad, Leyla
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
    Cheah, Chan Yoon
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Forbes, Sheryl G.
    Oki, Yasuhiro
    Fowler, Nathan H.
    BLOOD, 2015, 125 (21) : 3357 - 3359
  • [35] Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
    Pro, Barbara
    Horwitz, Steven M.
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Morschhauser, Franck
    Wilhelm, Martin
    Iyer, Swaminathan Padmanabhan
    Shustov, Andrei R.
    Wolfson, Julie
    Balser, Barbara E.
    Coiffier, Bertrand
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 914 - 917
  • [36] IMMUNOHISTOCHEMICAL DETECTION OF ZAP-70 IN A SERIES OF MARGINAL ZONE LYMPHOMA (MZL) PATIENTS
    Kalpadakis, C.
    Pangalis, G. A.
    Korkolopoulou, P.
    Vassilakopoulos, T. P.
    Levidou, G.
    Kyrtsonis, M. C.
    Sachanas, S.
    Yiakoumis, X.
    Dimitriadou, E. M.
    Kontopidou, F. N.
    Siakantaris, M. P.
    Patsouris, E.
    Panayiotidis, P.
    Papadaki, H.
    Angelopoulou, M. K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 404 - 404
  • [37] TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
    Clancy, Z.
    Bell, E.
    Chastek, B.
    Bunner, S.
    Copher, R.
    Arekapudi, S.
    VALUE IN HEALTH, 2020, 23 : S43 - S43
  • [38] Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
    Noy, Ariela
    de Vos, Sven
    Thieblemont, Catherine
    Martin, Peter
    Flowers, Christopher R.
    Morschhauser, Franck
    Collins, Graham P.
    Ma, Shuo
    Coleman, Morton
    Peles, Shachar
    Smith, Stephen
    Barrientos, Jacqueline C.
    Smith, Alina
    Munneke, Brian
    Dimery, Isaiah
    Beaupre, Darrin M.
    Chen, Robert
    BLOOD, 2017, 129 (16) : 2224 - 2232
  • [39] IDELALISIB MONOTHERAPY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA
    Li, J. J.
    Breuleux, M.
    Smith, C.
    Davies, A.
    HAEMATOLOGICA, 2016, 101 : 103 - 104
  • [40] Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open Label, Registration Directed Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 11
12345